EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 3.0

Real-World Comparative Evidence for Telitacicept, Glucocorticoids, and Nefecon in IgA Nephropathy: Clinical Value and Interpretive Considerations [Letter]

Jingyu Wang iD

Drug Design, Development and Therapy · 2026-08 · Volume 20 · 1-3

DOI: 10.2147/dddt.s639608 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-08. Verfasst von Jingyu Wang. Beteiligte Einrichtung: Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Institute of Nephrology, Zhejiang University, Zhejiang …. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with great interest the study by Li et al, who compared glucocorticoids, telitacicept, and Nefecon in 101 patients with biopsy-confirmed immunoglobulin A nephropathy (IgAN). 1 This study addresses a question that is increasingly relevant to nephrologists: how several disease-modifying options perform when used in routine practice rather than in separate, highly controlled trials.The authors should be commended for examining three clinically pertinent strategies within one center and a common 9-month observation window, while reporting remission, proteinuria, kidney function, and recorded adverse events.The study is particularly valuable when viewed alongside the evolving evidence base.Randomized trials have established that telitacicept can reduce proteinuria through dual BAFF/APRIL inhibition, 2,3 while NefIgArd and TESTING have clarified important benefits and trade-offs of targeted-release budesonide and systemic glucocorticoids, respectively.4,5 Earlier real-world studies of telitacicept have also reported proteinuria reduction and generally reassuring short-term tolerability, but many involved smaller cohorts, shorter follow-up, or comparisons with broader categories of supportive or immunosuppressive therapy.6,7 By placing telitacicept, Nefecon, and glucocorticoids in the same clinical setting, Li et al extend this literature in a way that is directly relevant to treatment selection.An important observation is that proteinuria declined and eGFR remained broadly stable in all three groups over 9 months.1 Although the between-group estimates require cautious interpretation, the trajectories suggest that each strategy may provide clinically meaningful short-term disease control in appropriately selected patients.The apparent differences in response tempo may also be informative.Glucocorticoids were associated with a rapid and pronounced reduction in proteinuria, whereas telitacicept appeared to achieve an intermediate trajectory and earlier partial remission than Nefecon at some time points.These patterns should not be read as a definitive ranking, but they generate a clinically relevant hypothesis: therapies acting at different points in the IgAN pathogenic pathway may differ not only in effect magnitude, but also in onset and depth of response.A larger longitudinal analysis could therefore examine treatment-by-time interactions rather than focusing only on a single 9-month comparison.The observational treatment-allocation process is central to interpreting these findings.The authors note that patients with proteinuria of at least 2 g/day were more likely to receive glucocorticoids. 1 Accordingly, baseline proteinuria and serum albumin differed among the groups, and the median baseline eGFR also varied to a clinically relevant degree.These differences are not simply methodological inconveniences; they reflect how clinicians individualize therapy according to disease severity, perceived urgency, treatment availability, and safety concerns.The study therefore captures a clinically meaningful mixture of drug effect and treatment-selection behavior.Its most defensible contribution is to Drug Design, Development and Therapy 2026

Autor:innen und Institutionen

  • Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Institute of Nephrology, Zhejiang University, Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzho…

ORCID-Profile: Jingyu Wang

Zitieren

APA

Wang, J. (2026). Real-World Comparative Evidence for Telitacicept, Glucocorticoids, and Nefecon in IgA Nephropathy: Clinical Value and Interpretive Considerations [Letter]. Drug Design, Development and Therapy, Volume 20, 1-3. https://doi.org/10.2147/dddt.s639608

Vancouver

Wang J. Real-World Comparative Evidence for Telitacicept, Glucocorticoids, and Nefecon in IgA Nephropathy: Clinical Value and Interpretive Considerations [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-3. doi:10.2147/dddt.s639608

BibTeX
@article{Wang2026,
  author = {Wang, Jingyu},
  title = {Real-World Comparative Evidence for Telitacicept, Glucocorticoids, and Nefecon in IgA Nephropathy: Clinical Value and Interpretive Considerations [Letter]},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--3},
  doi = {10.2147/dddt.s639608}
}
Kostenlos starten →